21 October 2025 : Original article
Low-Dose r-ATG vs Basiliximab in Low-Risk Living-Donor Kidney Transplantation: Outcomes in Acute Rejection, Graft Function, and Infections
Nam Ho
ABDEF 1, Thu Thi Nguyen BCDF 1, Nam Van Do BCD 1, Chi Tam Nguyen BEF 1, Su Xuan Hoang DEF 2, Khanh Vo Ngoc Hoang BEF 3, Trung Dinh Ngo ABDEF 1*
DOI: 10.12659/AOT.949942
Ann Transplant 2025; 30:e949942
Table 1 Baseline characteristics.
| Total (n=150) | Low-dose r-ATG (n=37) | Basiliximab (n=113) | P | |
|---|---|---|---|---|
| Age (yr), median (range) | 40 (29–51) | 39 (27–51) | 41 (30–52) | 0.398 |
| Sex (M/F) | 34/116 | 26/11 | 90/23 | 0.339 |
| BMI (kg/m) | 20.93 | 21.25 | 20.83 | 0.397 |
| Cause of ESRD | ||||
| GN (%) | 93 (62%) | 24 (64.9%) | 69 (61.06%) | |
| DM (%) | 6 (4%) | 1 (2.7%) | 5 (4.42%) | |
| HTN (%) | 45 (30%) | 11 (29.7%) | 34 (30.1%) | |
| PCKD (%) | 2 (1,33%) | 0 | 2 (1.77%) | |
| Other (%) | 4 (2,67%) | 1 (2.7%) | 3 (2.65%) | |
| Dialysis duration (months), median (range) | 17.95 | 13.51 | 19.40 | 0.143 |
| HLA Class I MM, Median (range) | 2 (0–4) | 2 (0–4) | 2 (0–4) | 0.092 |
| HLA Class II MM, median (range) | 1 (0–2) | 1 (0–2) | 1 (0–2) | 0.095 |
| CMV status (%) | 0.582 | |||
| Low-risk | 0 | 0 | 0 | |
| Intermediate-risk | 150 (100%) | 37 (100%) | 113 (100%) | |
| High-risk | 0 | 0 | 0 | |
| WIT mean (minutes) | 192.5 | 189 | 194 | 0.179 |
| CIT mean (minutes) | 61.13 | 57.2 | 62.4 | 0.2 |
| r-ATG – rabbit anti-thymocyte globulin; BSX – basiliximab; BMI – body mass index; CMV – Cytomegalovirus; ESRD – end-stage renal disease; DM – diabetes mellitus; HTN – hypertension; HLA – human leukocyte antigen; MM – mismatch; RRT – renal replacement therapy; GN – glomerulonephritis; PCKD – polycystic kidney disease; WIT – warm ischemia time; CIT – cold ischemia time. | ||||